DENOSUMAB (Prolia®)
Clinical Indication
Osteoporosis
Comments
Prolia® is the Reference (originator) product
In LLR Ponlimsi® 60mg PFS (denosumab biosimilar) is the First line choice for osteoporosis instead of Prolia®
Prolia® remains available for patients intolerant to biosimilar alternatives.
Date of classification
May 2014
Orange
Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.